Viking Q1 net loss $27.4M; VK2735 obesity drug shows up to 14.7% weight loss; cash $963M

Viking Therapeutics, Inc.

2024-Q1 EPS reported -$0.26

Q1 net loss $27.4M ($0.26/sh), R&D expense $24.1M, G&A $10.0M.
Phase 2 VENTURE: VK2735 hit primary endpoint; up to 14.7% weight loss from baseline, 13.1% placebo-adjusted at 13 weeks.
Phase 1 oral VK2735: up to 5.3% weight loss from baseline (3.3% placebo-adjusted) at 28 days; no SAEs; plan Phase 2 in obesity later 2024.
Phase 2b VOYAGE (VK2809 in NASH/fibrosis) 52-week histology data expected in 2Q24.
Q1 gross proceeds $632.5M from stock offering; cash & investments $963M as of Mar 31, 2024.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Viking Therapeutics, Inc. reported financial results for the first quarter ended March 31, 2024.

Period: the first quarter ended March 31, 2024
Result: reported results

Exact text from the filing

On April 24, 2024, we issued a press release reporting our financial results for the first quarter ended March 31, 2024 and providing a corporate update.

View on SEC.gov

1436 earnings releases filed in the last 30 days. Browse all earnings releases →

Viking Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-24-047567

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.